 |
Nanosensors in clinical development of CAR-T cell immunotherapy.
Nguyen-Le TA, Bartsch T, Wodtke R, Brandt F, Arndt C, Feldmann A, Sandoval Bojorquez DI, Roig AP, Ibarlucea B, Lee S, Baek CK, Cuniberti G, Bergmann R, Puentes-Cala E, Soto JA, Kurien BT, Bachmann M, Baraban L.
|
|
|
|
Efficient correction of oncogenic KRAS and TP53 mutations through CRISPR base editing.
Sayed S, Sidorova OA, Hennig A, Augsburg M, Cortes Vesga CP, Abohawya M, Schmitt LT, S R N D, Stange DE, Mircetic J, Buchholz F.Cancer Res. 2022 Jul 8:can.21.2519. doi: 10.1158/0008-5472.CAN-21-2519. Online ahead of print.
|
|
|
|
Immune dysfunction signatures predict outcomes and define checkpoint blockade-unresponsive microenvironments in acute myeloid leukemia.
Rutella S, Vadakekolathu J, Mazziotta F, Reeder S, Yau TO, Mukhopadhyay R, Dickins B, Altmann H, Kramer M, Knaus HA, Blazar BR, Radojcic V, Zeidner JF, Arruda A, Wang B, Abbas HA, Minden MD, Tasian SK, Bornhäuser M, Gojo I, Luznik L. J Clin Invest. 2022 Nov 1;132(21):e159579. doi: 10.1172/JCI159579.
|
|
|
|
Impact of IDH1 and IDH2 mutational subgroups in AML patients after allogeneic stem cell transplantation.
Kunadt D, Stasik S, Metzeler KH, Röllig C, Schliemann C, Greif PA, Spiekermann K, Rothenberg-Thurley M, Krug U, Braess J, Krämer A, Hochhaus A, Scholl S, Hilgendorf I, Brümmendorf TH, Jost E, Steffen B, Bug G, Einsele H, Görlich D, Sauerland C, Schäfer-Eckart K, Krause SW, Hänel M, Hanoun M, Kaufmann M, Wörmann B, Kramer M, Sockel K, Egger-Heidrich K, Herold T, Ehninger G, Burchert A, Platzbecker U, Berdel WE, Müller-Tidow C, Hiddemann W, Serve H, Stelljes M, Baldus CD, Neubauer A, Schetelig J, Thiede C, Bornhäuser M, Middeke JM, Stölzel F; A. M. L. Cooperative Group (AMLCG), Study Alliance Leukemia (SAL). J Hematol Oncol. 2022 Sep 5;15(1):126. doi: 10.1186/s13045-022-01339-8.
|
|
|
|
CAR T cells targeting Aspergillus fumigatus are effective at treating invasive pulmonary aspergillosis in preclinical models.
Seif M, Kakoschke TK, Ebel F, Bellet MM, Trinks N, Renga G, Pariano M, Romani L, Tappe B, Espie D, Donnadieu E, Hünniger K, Häder A, Sauer M, Damotte D, Alifano M, White PL, Backx M, Nerreter T, Machwirth M, Kurzai O, Prommersberger S, Einsele H, Hudecek M, Löffler J. Sci Transl Med. 2022 Sep 28;14(664):eabh1209. doi: 10.1126/scitranslmed.abh1209. Epub 2022 Sep 28.
|
|
|
|
Automated, scaled, transposon-based production of CAR T cells.
Lock D, Monjezi R, Brandes C, Bates S, Lennartz S, Teppert K, Gehrke L, Karasakalidou-Seidt R, Lukic T, Schmeer M, Schleef M, Werchau N, Eyrich M, Assenmacher M, Kaiser A, Prommersberger S, Schaser T, Hudecek M. J Immunother Cancer. 2022 Sep;10(9):e005189. doi: 10.1136/jitc-2022-005189.
|
|
|
|
ATRA works synergistically with the γ-secretase inhibitor crenigacestat to augment BCMA on multiple myeloma and the efficacy of BCMA-CAR T-cells.
García-Guerrero E, Rodríguez-Lobato LG, Sierro-Martínez B, Danhof S, Bates S, Frenz S, Haertle L, Götz R, Sauer M, Rasche L, Kortüm KM, Pérez-Simón JA, Einsele H, Hudecek M, Prommersberger SR. Haematologica. 2022 Sep 1. doi: 10.3324/haematol.2021.281339. Online ahead of print.
|
|
|
|
Differences in classification schemata for myelodysplastic/myeloproliferative overlap neoplasms.
Patnaik MM, Zeidan AM, Padron E, Platzbecker U, Sallman DA, DeZern AE, Bejar R, Sekeres M, Taylor J, Little RF, Bewersdorf JP, Kim TK, Kim N, Hourigan CS, Dela Porta MG, Stahl M, Steensma D, Xu ML, Odenike O, Carraway H, Fenaux P, Nazha A, Komrokji R, Loghavi S, Xie Z, Hasserjian R, Savona M, Bennett JM. Leukemia. 2022 Nov 5. doi: 10.1038/s41375-022-01754-3. Online ahead of print.
|
|
|
|
Finding consistency in classifications of myeloid neoplasms: a perspective on behalf of the International Workshop for Myelodysplastic Syndromes.
Zeidan AM, Bewersdorf JP, Buckstein R, Sekeres MA, Steensma DP, Platzbecker U, Loghavi S, Boultwood J, Bejar R, Bennett JM, Borate U, Brunner AM, Carraway H, Churpek JE, Daver NG, Della Porta M, DeZern AE, Efficace F, Fenaux P, Figueroa ME, Greenberg P, Griffiths EA, Halene S, Hasserjian RP, Hourigan CS, Kim N, Kim TK, Komrokji RS, Kutchroo V, List AF, Little RF, Majeti R, Nazha A, Nimer SD, Odenike O, Padron E, Patnaik MM, Roboz GJ, Sallman DA, Sanz G, Stahl M, Starczynowski DT, Taylor J, Xie Z, Xu M, Savona MR, Wei AH, Abdel-Wahab O, Santini V. Leukemia. 2022 Oct 20. doi: 10.1038/s41375-022-01724-9. Online ahead of print.
|
|
|
|
Neoantigen reactive T cells correlate with the low mutational burden in hematological malignancies.
Saini SK, Holmberg-Thydén S, Bjerregaard AM, Unnikrishnan A, Dorfmüller S, Platzbecker U, Tirado-Gonzalez I, Bönig H, El Fassi D, Grønbæk K, Pimanda J, Medyouf H, Hadrup SR. Leukemia. 2022 Nov;36(11):2734-2738. doi: 10.1038/s41375-022-01705-y. Epub 2022 Oct 8.
|
|
|
|
Compartment-specific mutational landscape of clonal hematopoiesis.
Hartmann L, Hecker JS, Rothenberg-Thurley M, Rivière J, Jentzsch M, Ksienzyk B, Buck MC, van der Garde M, Fischer L, Winter S, Rauner M, Tsourdi E, Weidner H, Sockel K, Schneider M, Kubasch AS, Nolde M, Hausmann D, Lützner J, Goralski S, Bassermann F, Spiekermann K, Hofbauer LC, Schwind S, Platzbecker U, Götze KS, Metzeler KH. Leukemia. 2022 Nov;36(11):2647-2655. doi: 10.1038/s41375-022-01700-3. Epub 2022 Sep 21.
|
|
|
|
Prospective validation of a biomarker-driven response prediction model to romiplostim in lower-risk myelodysplastic neoplasms - results of the EUROPE trial by EMSCO.
Kubasch AS, Giagounidis A, Metzgeroth G, Jonasova A, Herbst R, Diaz JMT, De Renzis B, Götze KS, Huetter-Kroenke ML, Gourin MP, Slama B, Dimicoli-Salazar S, Cony-Makhoul P, Laribi K, Park S, Jersemann K, Schipp D, Metzeler KH, Tiebel O, Sockel K, Gloaguen S, Mies A, Chermat F, Thiede C, Sapena R, Schlenk RF, Fenaux P, Platzbecker U, Adès L. Leukemia. 2022 Oct;36(10):2519-2527. doi: 10.1038/s41375-022-01669-z. Epub 2022 Sep 7.
|
|
|
|
Save the date - SaxoCell trainings and events
Dresden & Leipzig
